A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC
SOCRATES HCC will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour.
Primary Sponsor
Collaborating Groups
Australasian Gastro-Intestinal Trials Group (AGITG), Abdominal Radiology Group of Australia and New Zealand (ARGANZ) & Gastrointestinal Society of Australia (GESA)
Participating Centres
Accrual Target
218
Current Accrual
Trial Chairperson
Prof Alan Wigg, Flinders Medical Centre, SA, Australia
A/Prof David Pryor, Princess Alexandra Hospital, QLD, Australia
Trial Contact
SOCRATES_HCC@trog.com.au
Clinical Trial Registration
Related Post
All Australian sites open for SOCRATES HCC trial
5 March 2025: TRIAL UPDATE We’re excited to have
TRIAL IN FOCUS: DCIS delivers valuable evidence
4 March 2025: A decade on from the last
